Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival - an analysis of data from the ERA-EDTA Registry by Spithoven, Edwin M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Renal replacement therapy for autosomal dominant polycystic kidney
disease (ADPKD) in Europe: prevalence and survival - an analysis of data
from the ERA-EDTA Registry
Spithoven, Edwin M; Kramer, Anneke; Meijer, Esther; Orskov, Bjarne; Wanner, Christoph; Abad, Jose
M; Aresté, Nuria; de la Torre, Ramón Alonso; Caskey, Fergus; Couchoud, Cécile; Finne, Patrik; Heaf,
James; Hoitsma, Andries; de Meester, Johan; Pascual, Julio; Postorino, Maurizio; Ravani, Pietro;
Zurriaga, Oscar; Jager, Kitty J; Gansevoort, Ron T
Abstract: BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most
common renal disease requiring renal replacement therapy (RRT). Still, there are few epidemiological
data on the prevalence of, and survival on RRT for ADPKD. METHODS: This study used data from
the ERA-EDTA Registry on RRT prevalence and survival on RRT in 12 European countries with 208
million inhabitants. We studied four 5-year periods (1991-2010). Survival analysis was performed by
the Kaplan-Meier method and by Cox proportional hazards regression. RESULTS: From the first to the
last study period, the prevalence of RRT for ADPKD increased from 56.8 to 91.1 per million population
(pmp). The percentage of prevalent RRT patients with ADPKD remained fairly stable at 9.8%. Two-
year survival of ADPKD patients on RRT (adjusted for age, sex and country) increased significantly
from 89.0 to 92.8%, and was higher than for non-ADPKD subjects. Improved survival was noted for
all RRT modalities: haemodialysis [adjusted hazard ratio for mortality during the last versus first time
period 0.75 (95% confidence interval 0.61-0.91), peritoneal dialysis 0.55 (0.38-0.80) and transplantation
0.52 (0.32-0.74)]. Cardiovascular mortality as a proportion of total mortality on RRT decreased more
in ADPKD patients (from 53 to 29%), than in non-ADPKD patients (from 44 to 35%). Of note, the
incidence rate of RRT for ADPKD remained relatively stable at 7.6 versus 8.3 pmp from the first to the
last study period, which will be discussed in detail in a separate study. CONCLUSIONS: In ADPKD
patients on RRT, survival has improved markedly, especially due to a decrease in cardiovascular mortality.
This has led to a considerable increase in the number of ADPKD patients being treated with RRT.
DOI: 10.1093/ndt/gfu017
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-104138
Accepted Version
Originally published at:
Spithoven, Edwin M; Kramer, Anneke; Meijer, Esther; Orskov, Bjarne; Wanner, Christoph; Abad,
Jose M; Aresté, Nuria; de la Torre, Ramón Alonso; Caskey, Fergus; Couchoud, Cécile; Finne, Patrik;
Heaf, James; Hoitsma, Andries; de Meester, Johan; Pascual, Julio; Postorino, Maurizio; Ravani, Pietro;
Zurriaga, Oscar; Jager, Kitty J; Gansevoort, Ron T (2014). Renal replacement therapy for autoso-
mal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival - an analysis of
data from the ERA-EDTA Registry. Nephrology, Dialysis, Transplantation, 29 Suppl:iv15-iv25. DOI:
10.1093/ndt/gfu017
2
 
 
 
Renal replacement therapy for autosomal dominant polycystic 
kidney disease (ADPKD) in Europe: prevalence and survival— 
an analysis of data from the ERA-EDTA Registry 
 
 
 
Edwin M. Spithoven
1,*, Anneke Kramer
2,*, Esther Meijer
1
, Bjarne Orskov
3
, Christoph Wanner
4
, Jose 
M. Abad
5
, Nuria Aresté
6
, Ramón Alonso de la Torre
7
, Fergus Caskey
8
, Cécile Couchoud
9
, Patrik Finne
10
, 
James Heaf
11
, Andries Hoitsma
12
, Johan de Meester
13
, Julio Pascual
14
, Maurizio Postorino
15
, Pietro Ravani
16
, 
Oscar Zurriaga
17,18
,  Kitty J. Jager
2 
and Ron T. Gansevoort
1
, on behalf of the ERA-EDTA Registry**, the 
EuroCYST Consortium** and the WGIKD** 
1Department of Nephrology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, the Netherlands, 
2ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands, 
3Division of Nephrology, Copenhagen University Hospital, Roskilde, Denmark, 4Division of Nephrology, University Clinic, University of 
Würzburg, Würzburg, Germany, 5Departamento de Medicina Preventiva y Salud Pública, Universidad de Zaragoza, Zaragoza, Spain, 
6Department of Nephrology, University Hospital Virgen Macarena, Seville, Spain, 7Public Health Directorate, Asturias, Spain, 8Richard Bright 
Renal Unit, Bristol, UK, 9REIN Registry, Agence de la Biomedecine, Saint Denis La Plaine, France, 10Finnish Registry of Kidney Diseases, 
Helsinki, Finland, 11Department of Nephrology, University of Copenhagen, Herlev Hospital, Herlev, Denmark, 12Department of Nephrology, 
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 13Department of Nephrology, Dialysis and Hypertension, 
Nederlandstalige  Belgische Vereniging voor Nefrologie (Dutch Speaking Belgium Renal Registry)—NBVN, AZ Nikolaas, Sint-Niklaas, Belgium, 
14Department of Nephrology, Hospital del Mar, Barcelona, Spain, 15Clinical Epidemiology and Physiopathology of Renal Diseases and 
Hypertension, U.O.C. Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera di Reggio Calabria and CNR-IBIM, Reggio Calabria, Italy, 
16Department of Medicine and Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada, 17Subirección General de Epidemiología y 
Vigilancia de la Salud, Conselleria de Sanitat, Generalitat C. Valenciana, Valencia, Spain and 18Spanish Consortium of Epidemiology and Public 
Health Research (CIBERESP), Spain 
 
Correspondence and offprint requests to: E-mail: r.t.gansevoort@umcg.nl 
*
Both authors contributed equally. 
**
A list with names of collaborators is given in the Appendix. 
 
 
 
 
A B S T R A C T  
 
Background.  Autosomal dominant polycystic kidney disease 
(ADPKD) is the fourth most common renal disease requiring 
renal replacement therapy (RRT). Still, there are few epidemio- 
logical data on the prevalence of, and survival on RRT for 
ADPKD. 
Methods. This study used data from the ERA-EDTA Registry 
on  RRT prevalence and  survival on  RRT in  12 European 
countries with 208 million inhabitants. We studied four 5-year 
periods (1991–2010). Survival analysis was performed by the 
Kaplan–Meier method and by Cox proportional hazards 
regression. 
Results. From the ﬁrst to the last study period, the prevalence 
of RRT for ADPKD increased from 56.8 to 91.1 per million 
population ( pmp). The percentage of prevalent RRT patients 
with ADPKD remained fairly stable at 9.8%. Two-year survival 
of  ADPKD  patients  on  RRT  (adjusted  for  age,  sex  and 
 
 
  
country) increased signiﬁcantly from 89.0 to 92.8%, and was 
higher than for non-ADPKD subjects. Improved survival was 
noted for all RRT modalities: haemodialysis [adjusted hazard 
ratio for mortality during the last versus ﬁrst time period 0.75 
(95% conﬁdence interval 0.61–0.91), peritoneal dialysis 0.55 
(0.38–0.80) and transplantation 0.52 (0.32–0.74)]. Cardiovas- 
cular mortality as a proportion of total mortality on RRT de- 
creased more in ADPKD patients ( from 53 to 29%), than in 
non-ADPKD patients ( from 44 to 35%). Of note, the inci- 
dence rate of RRT for ADPKD remained relatively stable at 7.6 
versus 8.3 pmp from the ﬁrst to the last study period, which 
will be discussed in detail in a separate study. 
Conclusions.  In ADPKD patients on RRT, survival has im- 
proved markedly, especially due to a decrease in cardiovascular 
mortality. This has led to a considerable increase in the 
number of ADPKD patients being treated with RRT. 
 
Keywords: ADPKD, epidemiology, prevalence, survival, renal 
replacement therapy 
 
 
 
INT R ODUCT IO N 
Autosomal dominant  polycystic kidney disease (ADPKD) is 
the most common hereditary kidney disease. It affects ∼1 in 
every 1000 subjects of the general population [1]. The disease 
is characterized by progressive cyst formation, especially in the 
kidneys, leading to massive kidney enlargement, pain and hae- 
maturia. Most ADPKD subjects show progressive renal func- 
tion  decline  and  ∼70%  develop  end-stage  renal  disease 
between their fourth and seventh decade of life [2–4]. ADPKD 
occurs worldwide and in all races [5], and it is generally 
assumed that this patient group accounts for around 10% of all 
subjects who are dependent on renal replacement therapy 
(RRT). However, differences in prevalence between regions 
have been suggested [6]. 
The choice of renal replacement modality is dependent on 
several factors, including patient  choice, physicians’ advice 
and resource availability. For the last 20 years, three RRT mod- 
alities have been available; haemodialysis, peritoneal dialysis 
and kidney transplantation. In ADPKD, peritoneal dialysis 
may be complicated by an increased prevalence of abdominal 
wall hernias and lower dialysis efﬁciency because of reduced 
abdominal space secondary to the enlarged kidneys and liver 
[7]. This has raised concern as to whether peritoneal dialysis is 
a good treatment modality in ADPKD patients. Based on clini- 
cal experience and  evidence from small-scale observational 
studies [8, 9], however, new opinions have been formed and 
policy changed. It has recently even been suggested that per- 
itoneal dialysis may be associated with a better prognosis in 
ADPKD than in non-ADPKD patients [10]. 
The survival of patients with treated end-stage renal disease 
for ADPKD was described in the 1990s. These studies showed 
that ADPKD patients had better survival on RRT than non- 
ADPKD patients [10–12]. More recent studies have suggested 
a further improvement in survival, but these studies were per- 
formed in relatively small patient populations [13–15]. As a 
result  of  this  increased  survival, the  number  of  ADPKD 
 
patients on RRT and the associated costs for medical care may 
be expected to have increased. However, there is no recent 
comprehensive overview of trends  in prevalence, incidence, 
survival and costs associated with RRT for ADPKD. 
The European Renal Association–European Dialysis and 
Transplant Association (ERA-EDTA) Registry and the Euro- 
CYST consortium have initiated a project to increase knowl- 
edge of the epidemiology of RRT for ADPKD in Europe. As 
part of this project, we investigated the prevalence of RRT and 
survival after start of RRT (overall and per speciﬁc treatment 
modality) for patients with ADPKD across Europe. Due to the 
abundance of information data on RRT, incidence will be re- 
ported in a separate study. 
 
 
M A TE R I AL S A N D M ET H O D S 
 
Data collection 
The study population consisted of RRT patients included in 
the ERA-EDTA Registry, which collects data from 24 national 
and regional registries in 12 European countries covering a 
population of 208 million people. Individual patient data, in- 
cluding date of birth, sex, primary renal disease, treatment 
modality history (haemodialysis, peritoneal dialysis and trans- 
plantation) and date and cause of death were derived from the 
national registries of Austria, Denmark, Finland, France, 
Greece, Romania, Sweden, the Netherlands and England, 
Wales, Northern Ireland, Scotland (the United Kingdom), and 
from the regional registries of Dutch and French-speaking 
Belgium, Calabria (Italy), Andalusia, Aragon, Asturias, Basque 
Country,  Cantabria,  Castile and  León, Castile-La Mancha, 
Catalonia, Extremadura, Galicia and Valencian region (Spain). 
Information on all RRT patients was used, except for Belgium, 
Spain (Cantabria, Castile and Leon and Castile-La Mancha) 
and the United Kingdom (except Scotland) from whom only 
information  on patients >20 years of age was provided. As 
ADPKD patients rarely reach end-stage renal disease before 
this age, this limitation was not expected to inﬂuence results 
on prevalence of RRT for ADPKD. Registries from the follow- 
ing countries/regions provided complete information for all 
years within the study period: Andalusia (Spain), Austria, 
Basque Country  (Spain), Catalonia  (Spain), Denmark, 
Finland, French-speaking Belgium, Greece, Sweden, Scotland, 
the Netherlands and Valencia (Spain). For Belgium, Spain and 
the United Kingdom (except Scotland that provided complete 
data for the whole period), participation rates increased over 
time. Information on participation rates is shown in Sup- 
plementary data Table 1. 
 
Deﬁnition 
The primary renal disease for which RRT was started was 
assessed using the ERA-EDTA coding system [16]. Two ERA- 
EDTA primary renal disease codes can be used for ADPKD: 
40 (unspeciﬁed polycystic kidney disease) and 41 ( polycystic 
kidney disease adult type). Among countries, a substantial 
variation (0.1–3.4%) in the mean prevalence of code 40 was 
observed (see Supplementary data Table 2). We combined 
codes 40 and 41 for the deﬁnition of ADPKD, because the 
 prevalence of non-ADPKD polycystic kidney disease is ex- 
pected from clinical experience to be very low, and unlikely to 
account for ﬁgures such as 3.4%. 
 
Data analysis 
The prevalence of RRT and  survival after start  of RRT 
(overall and per speciﬁc treatment modality) were studied for 
ADPKD patients and compared with data for non-ADPKD 
patients (all other RRT patients). 
Prevalence was studied in four consecutive 5-year periods 
(1991–95, 1996–2000, 2001–05 and  2006–10). For each 
period, we calculated for participating registries the average 
prevalence of RRT for ADPKD as the sum of the prevalence of 
ADPKD patients alive and on RRT on 31 December of 5 sub- 
sequent years divided by the sum of the total general popu- 
lation covered by that registry in the same 5 years. Treatment 
modality was deﬁned as the treatment patients were attending 
at 31 December of each year. The age and sex distribution of 
the 2005 EU27 population as provided by Eurostat [17] was 
used to adjust for age and sex, to allow evaluation of trends in 
time and differences among countries. To investigate the 
association between prevalence of RRT for ADPKD versus for 
non-ADPKD, we used weighted least squares regression analy- 
sis to take country-speciﬁc population sizes into account. 
Survival analyses for RRT were performed on incident RRT 
patients. In addition, survival analyses for dialysis were per- 
formed on incident dialysis patients, where treatment modality 
at Day 91 after the start of RRT was used to categorize subjects 
into haemodialysis or peritoneal dialysis. For kidney transplant 
recipients, survival analyses were performed using data after the 
ﬁrst transplantation, i.e. such patients could have been on dialy- 
sis before transplantation. We used the Kaplan–Meier method 
and Cox proportional hazards regression to calculate crude and 
adjusted survival. Data on 2-year survival was used, because 
2-year survival was known for all four study periods under 
investigation. For all survival analyses, death  was the  event 
studied and reasons for censoring were loss to follow-up or the 
end of the follow-up period. Additionally, for survival analyses 
for dialysis, kidney transplantation was also considered as a cen- 
sored observation. To allow evaluation of trends over time, and 
comparisons between ADPKD and non-ADPKD patients, sur- 
vival analyses were adjusted for age, sex, primary renal disease 
and country. In addition, survival analyses were performed for 
patients with primary glomerulonephritis (ERA-EDTA primary 
renal disease codes 10–19) as an extra control group. Survival 
analyses were only performed using data from registries that 
had information over the entire study period (i.e. from 1991 
through 2010). Patient survival was calculated not only for the 
overall RRT population, but also for a speciﬁc age group (age 
60–65 years at start RRT). For analyses of cause of death, only 
data from registries reporting <25% missing or unknown causes 
of death were included. These registries are Austria, Belgium 
(French-speaking), Denmark, Finland, Greece, Spain (Andalu- 
sia, Basque Country, Catalonia and Valencian region), Sweden 
and the Netherlands. Cause of death was coded using the ERA- 
EDTA coding system [16]. For analyses of cause of death, RRT 
modality was determined  at 2-year follow-up, or at 60 days 
prior to death in the case of patients who died before 2-year 
follow-up. Regression and survival analyses were carried out 
using SAS version 9.2. 
To determine the economic burden associated with end- 
stage renal disease for ADPKD, the costs involved with RRT 
were estimated. Country-speciﬁc information obtained from 
the literature was used. For costs involved with haemodialysis 
and peritoneal dialysis, data were obtained from: Austria [18], 
Belgium [19], Denmark [20], Finland [21], France [22], Greece 
[23], Italy [24], Romania [25], Spain [26], Sweden [27], the 
Netherlands [28] and the UK [29]. For costs involved with 
transplantation  ( ﬁrst  and  subsequent years), data were ob- 
tained from: Austria [18], Finland [21], France [22], Greece 
[23], the Netherlands [28] and Spain [26]. Costs were adjusted 
for currency, and for inﬂation by harmonized indices of con- 
sumer prices as provided by Eurostat. For each RRT treatment 
modality, the average of the costs obtained from these 
countries was calculated, together with a 95% conﬁdence in- 
terval (95% CI). These numbers were multiplied by the total 
number of prevalent ADPKD patients per RRT treatment 
modality in 2010 and summed. 
 
 
R E S U L T S 
 
Prevalence of RRT 
Between 1991  and  2010, a  total  of  437 496  prevalent 
patients from 12 countries received RRT; 35 164 patients with 
ADPKD and 402 332 non-ADPKD patients. Of these patients, 
265 866  were  male  (61%)  (18 588  ADPKD  patients  and 
247 278 non-ADPKD patients). Table 1 shows the age- and 
sex-adjusted prevalence of ADPKD subjects on RRT for the 
participating  countries  during  four  consecutive periods  of 
5 years. Having observed differences in crude prevalence 
among European countries, we standardized for the age and 
sex of the 2005 EU27 population, but  differences persisted 
(Table 1). Prevalence in Denmark, Italy (Calabria), Romania 
and the UK was below the mean (91.1 per million population 
[ pmp]) whereas, in Belgium, France, Spain and Sweden, the 
prevalence was above the  mean.  Figure 1  visualizes these 
differences geographically. Figure 2 shows per country  the 
prevalence of RRT for ADPKD versus the prevalence of RRT 
for  non-ADPKD  in  the  same  time  period  (2006 through 
2010), standardized for age and sex to the 2005 EU27 popu- 
lation. This ﬁgure shows a clear positive correlation (R2 = 
0.936, P < 0.001), indicating  that  in  countries  with  a  high 
overall number of non-ADPKD patients on RRT, there is also 
a high number of ADPKD patients on RRT. 
 
Trends in prevalence of overall RRT 
The average prevalence of ADPKD patients receiving RRT 
increased by 60.4% from 56.8 pmp in 1991–95 to 91.1 pmp in 
2005–10 (Table 1). While the prevalence of RRT for ADPKD 
has increased markedly in Greece and Finland there has been 
only a modest increase in other countries, such as Denmark 
and the Netherlands. Figure 3 shows the percentage of preva- 
lent RRT patients with ADPKD for each country and the 
average for the participating registries with a complete follow- 
up. The average percentage has remained fairly stable over 
 Table 1.  Prevalence of ADPKD patients  receiving renal replacement  therapy (RRT) overall (upper  panel), and subdivided in dialysis (middle panel) or 
living with a kidney transplant (lower panel) 
 
 
All RRT 
 
1991–1995 ( pmp) 
 
1996–2000 ( pmp) 
 
2001–2005 ( pmp) 
 
2006–2010 ( pmp) 
 
Changea (%) 
Austriab 47.4 60.4 73.0 81.4 +71.7 
Belgiumc 51.4 72.5 88.9 104.1 NA 
Denmarkb  47.4 55.4 64.1  71.1 +50.0 
Finlandb  44.0 62.9 79.1 87.9 +99.8 
France    101.5   NA 
Greeceb 38.6 58.1 72.0  78.5 +103.4 
Italy, Calabria  64.7 69.5  72.9 NA 
Romania     35.9 NA 
Spainc 80.8 91.5 93.0 103.0 +27.5 
Swedenb 64.7 77.1 90.4 100.0 +54.6 
The Netherlandsb  56.3 65.0 72.2 80.2 +42.5 
United Kingdomc 46.4 55.4 61.9 75.6 NA All 
countriesd      56.8   70.3   82.1  91.1  +60.4 
Dialysis 
Austriab 22.4 28.3 30.9 32.3 +44.2 
Belgiumc 33.3 33.1 34.6 37.6 NA 
Denmarkb  22.8 28.9 33.8 33.7 +47.8 
Finlandb  17.9 21.1 23.4 22.5 +25.7 
France    39.5 NA 
Greeceb 32.0 48.3 56.0 56.0 +75.0 
Italy, Calabria  57.1 57.7 53.4 NA 
Romania    34.4 NA 
Spainc 54.2 47.4 39.9 39.4 NA 
Swedenb 22.7 26.4 31.1 31.6 +39.2 
The Netherlandsb  28.8 29.3 30.3 26.8 − 6.9 
United Kingdomc 20.7 23.4 26.2 29.9 NA 
All countriesd  32.1 35.8 37.8 37.3 +16.2 
Transplantation 
Austriab 25.0 32.1 42.1 49.1 +96.4 
Belgiumc 18.1 39.4 54.3 66.3 NA 
Denmarkb  24.6 26.4 30.1 37.0 +50.4 
Finlandb  26.1 41.8 55.7 65.5 +151.0 
France    61.6   NA 
Greeceb 6.6 9.8 15.9 22.4 +239.4 
Italy, Calabria   7.7 11.8 19.5 NA 
Romania       1.4 NA 
Spainc 26.2 43.5 52.8 63.5 NA 
Swedenb 42.0 50.7 59.3 68.4 +62.9 
The Netherlandsb  27.5 35.8 41.8 53.4 +94.2 
United Kingdomc 25.7 29.9 34.3 45.3 NA All 
countriesd      24.6   34.4   44.2  53.8  +118.7 
 
All data are standardized to the age and sex distribution of the 2005 EU27 population and expressed per million population ( pmp). NA, not applicable or available (due to change in 
coverage over time). 
aChange between 1991–1995 and 2006–2010. 
bCountry with complete coverage during all four periods. 
cCoverage of the general population by the renal registry increasing over time, see for details Supplementary data Table 1. 
dAverage of countries with complete coverage during all four periods. 
 
 
 
time (9.9% in 1991–95 versus 9.8% in 2006–10), with some ex- 
ceptions at the country level. 
 
Trends in prevalence of speciﬁc RRT modalities 
Over the past 20 years, the prevalence of ADPKD patients 
treated with the various RRT modalities has changed. The 
prevalence of haemodialysis increased from 25.2 to 32.0 
pmp, peritoneal dialysis increased from 3.8 to 5.3 pmp and 
kidney  transplantation   increased  from  22.3  to  53.8 pmp 
(1991–96 versus 2006–10, respectively). In ADPKD patients, 
the relative contribution  to overall RRT decreased for hae- 
modialysis from 49.1 to 35.1%, whereas that  of peritoneal 
dialysis decreased from 7.4 to 5.8%, and that of kidney trans- 
plantation  increased from 43.5 to 59.1%. Of note, in non- 
ADPKD patients, the relative contribution to overall RRT of 
haemodialysis remained stable at 48.0%, whereas peritoneal 
dialysis decreased from 9.7 to 7.1% and kidney transplan- 
tation increased only slightly from 41.2 to 44.1%. Figure 4 
shows the contribution of haemodialysis, peritoneal dialysis 
and kidney transplantation as a percentage of overall preva- 
lent   RRT  population   in   ADPKD  versus  non-ADPKD 
patients in the period 2006–10. It indicates that peritoneal 
dialysis is as frequently applied as a treatment  modality in 
ADPKD  as  in  non-ADPKD  patients,  whereas  ADPKD 
  
 
 
 
 
 
 
 
 
 
 
 
F I G U R E 1 : Prevalence of renal replacement therapy (RRT) for 
patients with ADPKD. Data are the average of the period 2006 
through 2010, expressed per million population ( pmp), and adjusted 
for age and sex distribution of the 2005 EU27 population. 
 
 
 
F I G U R E 2 : Prevalence of RRT for patients with ADPKD versus 
non-ADPKD kidney diseases. Data are the average of the period 2006 
through 2010, expressed per million population, and adjusted for age 
and sex to the distribution of the 2005 EU27 population. The size of 
marker denotes the size of the general population under study. AT, 
Austria; BE, Belgium; DK, Denmark; ES, Spain; FI, Finland; FR, 
France; GR, Greece; IT, Italy, Calabria; NL, the Netherlands; RO, 
Romania; SE, Sweden; UK, United Kingdom. 
 
patients are more likely to be kidney transplant  recipients 
(especially from a deceased donor rather than a living donor, 
Supplementary data Figure 1). 
F I G U R E 3 : Trends in prevalence of ADPKD patients on RRT as 
percentage of the total population on renal replacement therapy. AT, 
Austria; BE, Belgium; DK, Denmark; ES, Spain; FI, Finland; FR, 
France; GR, Greece; IT, Italy, Calabria; NL, the Netherlands; RO, 
Romania; SE, Sweden; UK, United Kingdom. *Coverage increasing 
over time, see for details Supplementary data Table 1. +All countries 
with complete follow-up coverage. 
 
Trends in survival 
The incidence rate of RRT for ADPKD remained relatively 
stable at 7.6 versus 8.3 pmp [30]. The crude 2-year survival 
rate of incident ADPKD patients starting RRT increased from 
88.3% in 1991–95 to 90.8% in 2006–10. When using the ﬁrst 
time period as reference, this corresponds with a hazard ratio 
(HR) for total mortality in the later study period of 0.77 (95% 
CI  0.66–0.90) (Table 2). When  adjusted  for  age, sex and 
country, the HR for total mortality was even lower at 0.64 
(95% CI 0.55–0.75), indicating that 2-year mortality has de- 
creased by 36% in the most recent compared with the ﬁrst 
time  period  (Table  2).  When  the  dialysis modalities  are 
studied separately, it shows that adjusted mortality decreased 
by 45% in ADPKD patients starting peritoneal dialysis, 
whereas mortality decreased by only 25% in ADPKD patients 
starting haemodialysis. The adjusted mortality of kidney trans- 
plantation recipients decreased by 48% (Table 2). The adjusted 
survival on RRT is higher in female than  in male ADPKD 
patients (Supplementary data Table 3), and is higher in 
ADPKD patients than  in non-ADPKD patients (overall, as 
well as when only patients with primary glomerulonephritis 
were studied as control group, Supplementary data Table 4). 
The average age at which dialysis is started, or the transplan- 
tation  is performed, may differ between ADPKD and non- 
ADPKD patients. Therefore, we calculated also survival rates 
for a speciﬁc age group (60–65 years) to allow a fair compari- 
son between ADPKD and non-ADPKD. Figure 5 shows that, 
also in this age group, ADPKD patients starting dialysis, or re- 
ceiving a kidney transplant, have a higher survival compared 
with non-ADPKD patients. 
 
Trends in causes of death 
The primary causes of death were divided into ﬁve cat- 
egories  (Figure  6).  Cardiovascular  disease  was  the  most 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F I G U R E 4 : Patients on haemodialysis (upper panel), peritoneal dialysis (middle panel) and living with a kidney transplant (lower panel) as 
percentage of the total population on RRT with ADPKD versus non-ADPKD. Data are the average of the period 2006 through 2010, and ad- 
justed for age and sex to the distribution of the EU27 population in 2005. The size of marker denotes the size of the general population under 
study. AT, Austria; BE, Belgium; DK, Denmark; ES, Spain; FI, Finland; FR, France; GR, Greece; IT, Italy, Calabria; NL, the Netherlands; RO, 
Romania; SE, Sweden; UK, United Kingdom. 
 
 
common cause of death in both ADPKD and non-ADPKD 
patients. During the study period, the relative contribution of 
cardiovascular mortality to total mortality decreased from 53 
to 29% (a decrease of 44%) in ADPKD patients and from 44 to 
35% (a decrease of 20%) in non-ADPKD patients. These data 
indicate that, in 1991–95, the relative contribution of cardio- 
vascular mortality to total mortality was higher in ADPKD 
patients than in non-ADPKD patients whereas, in 2006–10, 
the  opposite was true. Additional analyses showed that,  in 
ADPKD patients,  stroke  mortality  decreased from  10.0 to 
6.7% (a decrease of 33%) in 1990–95 to 2006–10. In a sensi- 
tivity analysis using an extended deﬁnition for cardiovascular 
mortality, i.e. adding mortality due to unknown causes to car- 
diovascular mortality per se, an even more pronounced 
reduction in cardiovascular mortality was noted in ADPKD 
patients when compared with non-ADPKD patients (a de- 
crease of 23 versus 13%, respectively). No difference in cardio- 
vascular mortality was observed between male and female 
patients (Supplementary data Table 5). Furthermore, we inves- 
tigated for ADPKD patients the causes of death per treatment 
modality separately. For kidney transplant recipients, the rela- 
tive contribution of cardiovascular mortality to total mortality 
decreased from 64.4 to 7.5%, for haemodialysis from 50.3 to 
26.5% and for peritoneal dialysis from 46.3 to 32.6%. 
 
Costs involved with RRT 
 
This  sub-study  includes  data  from  12  registries  (Sup- 
plementary data Table 6) and comprises ∼42% of the total 
population of the 27 European Union countries. In this popu- 
lation, the costs involved with RRT for the 20 983 prevalent 
 Table 2.  Two-year patient survival rate and hazard ratio for mortality in ADPKD patients starting RRT, dialysis or receiving a ﬁrst kidney transplant 
 
Two-year survival 
 
Hazard ratio 
 
All RRT N Crude Adjusteda Crude Adjustedb 
 
1991–1995 2756 88.3 (87.1–89.3) 89.0 (87.8–90.2) 1 (ref ) 1 (ref ) 
1996–2000 3279 88.9 (87.9–89.8) 90.3 (89.3–91.3) 0.94 (0.81–1.10) 0.88 (0.75–1.02) 
2001–2005 3547 89.4 (88.5–90.3) 91.6 (90.7–92.5) 0.90 (0.77–1.04) 0.75 (0.65–0.88) 
2006–2010 3708 90.8 (89.9–91.7) 92.8 (92.0–93.6) 0.77 (0.66–0.90) 0.64 (0.55–0.75) 
Haemodialysis 
1991–1995 1984 89.0 (87.6–90.3) 90.4 (89.0–91.7) 1 (ref ) 1 (ref ) 
1996–2000 2488 88.1 (86.9–89.3) 90.2 (89.0–91.4) 1.10 (0.91–1.33) 1.03 (0.85–1.25) 
2001–2005 2573 88.5 (87.3–89.6) 91.5 (90.4–92.6) 1.07 (0.88–1.29) 0.89 (0.73–1.07) 
2006–2010 2550 90.2 (89.0–91.3) 92.8 (91.8–93.9) 0.90 (0.74–1.10) 0.75 (0.61–0.91) 
Peritoneal dialysis 
1991–1995 606 86.2 (83.2–88.6) 88.0 (84.6–91.5) 1 (ref ) 1 (ref ) 
1996–2000 622 91.9 (89.4–93.8) 92.9 (90.5–95.3) 0.57 (0.39–0.84) 0.58 (0.39–0.86) 
2001–2005 748 93.8 (91.7–95.3) 94.6 (92.7–96.5) 0.42 (0.28–0.62) 0.42 (0.28–0.63) 
2006–2010 789 91.7 (89.4–93.5) 93.1 (90.9–95.3) 0.57 (0.40–0.82) 0.55 (0.38–0.80) 
Transplantation 
1991–1995 815 94.2 (92.5–95.6) 90.6 (87.9–93.4) 1 (ref ) 1 (ref ) 
1996–2000 1505 94.8 (93.6–95.8) 91.9 (90.0–93.8) 0.90 (0.62–1.29) 0.86 (0.60–1.24) 
2001–2005 1862 95.3 (94.2–96.1) 93.2 (91.7–94.6) 0.82 (0.57–1.17) 0.72 (0.50–1.03) 
2006–2010 2538 96.4 (95.6–97.1) 94.9 (93.8–96.1) 0.60 (0.42–0.86) 0.52 (0.36–0.74) 
 
Hazard ratios are based on 2-year survival. 
aAdjusted for ﬁxed values of age (at start RRT/dialysis or kidney transplantation), sex and country. 
bAdjusted for age (at start RRT/dialysis or kidney transplantation), sex and country. 
 
 
 
 
 
 
F I G U R E 5 : Trends in 2-year patient survival in ADPKD versus non-ADPKD patients aged 60–65 years starting RRT, dialysis or receiving a 
ﬁrst kidney transplant. Adjusted for age at start RRT, sex and primary renal disease (diabetes, hypertension, glomerulonephritis and other). 
Survival probabilities are standardized according to the following ﬁxed values: age = 60, males = 60%, diabetes = 20%, hypertension = 17% and 
glomerulonephritis = 15%). RRT, renal replacement therapy; HD, haemodialysis; PD, peritoneal dialysis; RTR, renal transplant recipients. 
 
 
 
ADPKD patients receiving RRT in 2010 (number of patients 
on haemodialysis 7457, peritoneal dialysis 1078, ﬁrst year of 
transplantation  1636 and  later after transplantation  10 812) 
are estimated to be ∼651 million euro per year with a 95% CI 
of 473–829 million euro. Using these data, it can be extrapo- 
lated that in the 27 countries that are part of the European 
Union,  ∼50 000  ADPKD patients  received RRT in  2010, 
and that the costs involved with RRT for these patients were 
1.5 billion euro (95% CI 1.1–2.0 billion euro). 
 
D I S C U S S I O N  
 
This study shows that across Europe the prevalence of 
ADPKD patients being dependent on RRT has increased con- 
siderably between 1991–95 and 2006–10. It also indicates that 
the relative contribution of ADPKD to end-stage renal disease 
for which RRT is started has remained fairly stable during this 
period (∼10%). When compared with non-ADPKD patients 
  
 
 
F I G U R E 6 : Trends in causes of death in patients on renal replacement therapy for ADPKD and non-ADPKD. Adjusted for average age and 
gender distribution of all patients starting RRT between 1991 and 2010. CV, cardiovascular. 
 
on RRT, ADPKD patients are as likely to be receiving perito- 
neal dialysis and more likely to be living with a kidney trans- 
plant. The survival of ADPKD patients on RRT has improved 
signiﬁcantly, mainly due to a marked reduction in cardiovas- 
cular mortality. 
Differences in the prevalence of RRT for ADPKD were ob- 
served among the countries participating in the ERA-EDTA reg- 
istry. There are at least three possible explanations for these 
differences. First, a difference in prevalence could be explained 
by a difference in general population structure among the 
countries. However, after standardization for age and sex to the 
2005 EU27 population differences in prevalence remained. 
Second, the prevalence of the disease itself may be different 
between the participating countries. Several studies from 
Germany, France, Portugal and the United Kingdom have tried 
to establish country-speciﬁc ADPKD prevalence data [31–34]. 
Unfortunately, different methods were used in these studies 
making it difﬁcult to draw ﬁrm conclusions on this issue. Third, 
the participating countries may have different policies with 
respect to acceptance of patients for RRT programmes. Interest- 
ingly, we found that the ratio of ADPKD versus non-ADPKD 
patients on RRT was remarkably stable between countries. 
Countries with a low overall number of patients receiving RRT 
have also a low number of ADPKD patients receiving RRT and 
vice versa. It seems unlikely that countries with a low or high 
prevalence of ADPKD will have a proportionally low or high 
prevalence of non-ADPKD chronic kidney disease. These data 
raise the possibility that differences among countries in preva- 
lence of RRT for ADPKD are a reﬂection of differences in RRT 
acceptance policies that are dependent on social and economic 
motivations [35, 36], but it may also be that prevention or 
primary care is better in some countries, which affect ADPKD 
and non-ADPKD to the same extent. However, as yet there is no 
treatment of which it is known to affect the course of ADPKD. 
With respect to the different RRT modalities, we observed 
that kidney transplantation is a more frequently used modality 
in  ADPKD patients  compared  with non-ADPKD  patients. 
This is in line with literature [11]. A case–control study from 
the USRDS found that ADPKD patients were transplanted at a 
2-fold higher rate than controls. This may be due to the fact 
that, in general, ADPKD patients are younger when they reach 
end-stage renal disease than non-ADPKD patients [30]. 
However, even after adjustment for age, it appeared that more 
ADPKD patients were kidney transplant recipients than non- 
ADPKD patients, especially of kidneys of deceased donors 
(Supplementary data Figure 1). It may well be that this is due 
to ADPKD patients having less co morbidity and therefore 
they are more likely to be accepted on the transplant waiting 
list. With respect to peritoneal dialysis, ADPKD patients were 
as likely to be on  this treatment  modality as non-ADPKD 
patients, and mortality in these ADPKD patients after starting 
peritoneal dialysis was lower. Of course, selection bias should 
be considered, because patients with very large polycystic 
kidneys and/or  livers may be offered peritoneal dialysis less 
often [37], but these data suggest that peritoneal dialysis is a 
safe treatment option in ADPKD patients that reach end-stage 
renal disease. 
We observed a 60.4% increase in the prevalence of ADPKD 
subjects on RRT from 1991–95 to 2006–10. The prevalence of 
RRT is inﬂuenced predominantly by two factors, incidence of 
RRT and survival on RRT. We have observed in the countries 
participating in the ERA-EDTA registry that the incidence rate 
of RRT for ADPKD remained relatively stable at 7.6 pmp in 
1991–95 versus 8.3 pmp in 2006–10 [30]. Because of the abun- 
dance of information, data on incident RRT will be presented 
in detail in a separate report. In contrast, survival on RRT has 
improved considerably in ADPKD patients, making it the 
major contributing factor to the increase in the number  of 
ADPKD patients being dependent on RRT. In line with the lit- 
erature, we have shown that ADPKD patients have a better 
survival compared with non-ADPKD patients, even after age 
and sex adjustment [12]. Further, we add to the existing litera- 
ture that ADPKD patients have better survival than patients 
with a kidney-localized disease (i.e. patients with primary glo- 
merulonephritis, Supplemental data Table 4). Of note, the 
choice for a speciﬁc RRT modality is not a random process, 
  
but inﬂuenced by personal preferences of patients and their 
treating physicians. In addition, for this analysis, the survival 
of dialysis patients was determined  from the start  of RRT, 
whereas the survival of kidney transplant recipients was deter- 
mined from the date of their ﬁrst transplant, and many will 
have been treated with dialysis before their transplantation. 
These considerations mean that survival should not be com- 
pared between the various RRT treatment modalities, but they 
do allow evaluations of trends in time per treatment modality 
and comparisons between ADPKD and non-ADPKD patients 
per treatment modality. 
The increase in survival that we observed is especially due 
to a marked reduction in cardiovascular mortality, which was 
more evident in ADPKD patients than in non-ADPKD 
patients. This reduction in cardiovascular mortality was not 
caused by a reduction in stroke, but mainly due to a decrease 
in non-stroke cardiovascular mortality. The cause of this im- 
provement in cardiovascular mortality cannot be concluded 
from the present study. Observational studies have suggested 
that better risk factor management before and after start of 
RRT (i.e. improved blood pressure and cholesterol control) 
and   improvements   in   quality  of  coronary   interventions 
(i.e. CABGs and PCIs) may have played a role [38–41], but it 
could also be due to an improvement in quality of RRT. 
The costs involved with RRT for ADPKD for the EU27 
zone in 2010 were estimated to be ∼1.5 billion euro (95% CI 
1.1–1.9 billion euro). To reduce the economic burden for the 
community at large, and of course to reduce the loss of quan- 
tity and quality of life of ADPKD patients, it is of utmost 
importance to prevent end-stage renal disease in this patient 
group. For a long time, no treatment options were available to 
prevent renal function decline in this patient group. Recently, 
however, it has been shown in a large-scale RCT that the use 
of the vasopressin V2 receptor antagonist tolvaptan are associ- 
ated with a decrease in rate of kidney growth and renal func- 
tion decline when compared with placebo [42]. However, this 
drug has not yet been registered for the indication ADPKD 
and is associated with side effects. Other treatment options are 
therefore necessary. A limited number  of these have been 
tested in clinical trials and, sometimes, the results were prom- 
ising [43–46]. The efﬁcacy of these novel treatments, however, 
needs conﬁrmation in large-scale RCTs before they can be pre- 
scribed in clinical practice. Given these considerations, more 
funding for ADPKD-related clinical care and research is ur- 
gently needed to  allow studies developing and  testing new 
therapies. 
We acknowledge that this study has limitations. Firstly, the 
costs involved with RRT are difﬁcult to determine. Country- 
speciﬁc data on costs associated with RRT were obtained from 
the literature, but they differ with respect to costs that  are 
taken into account. Some countries included costs of for in- 
stance medication, stafﬁng and laboratory analyses, whereas 
other countries did not. The costs involved with RRT for 
ADPKD that we calculated should therefore be used as an esti- 
mate rather than as an exact ﬁgure. It should be noted that the 
true economic burden is likely to be considerably higher than 
this ﬁgure, because it only relates to medical costs involved 
with RRT and not costs associated with for instance the loss of 
 
money-earning capacity and the medical complications of the 
affected patients. Secondly, not all countries in the European 
Union are participating in the ERA-EDTA Registry and for 
participating registries detailed information was not complete 
for all time periods. Average values for the evaluation of trends 
in time and survival analyses were, therefore, only calculated 
for countries that did have complete datasets during the four 
study periods. Notwithstanding, this study still covers 42% of 
the  inhabitants  of the  European  Union,  representing more 
than 200 million people. This study reports, therefore, on by 
far the most comprehensive epidemiological dataset on 
ADPKD to date. The study also took into account not only 
ADPKD, but also non-ADPKD patients on RRT, studied the 
prevalence of RRT overall and  per treatment  modality and 
investigated trends  in  RRT prevalence and  survival over a 
20-year time period. 
In summary, these data provide the most comprehensive 
insight thus far into the epidemiology of end-stage renal 
disease for ADPKD for which RRT has been started. These 
data show that, in Europe, the prevalence of RRT for ADPKD 
has markedly increased during the last two decades, but that 
the relative contribution of ADPKD to the overall RRT popu- 
lation has remained stable at ∼10%. Importantly, the survival 
of  ADPKD  patients  on  RRT  has  increased  signiﬁcantly, 
mainly due to a reduction in cardiovascular mortality. 
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